NEW YORK, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc., a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, announced today that Lawrence S. Lamb, Ph.D., Professor of Medicine and Director of the Cell Therapy Laboratory at the University of Alabama at Birmingham (UAB) and Scientific Co-Founder of Incysus, will present at a scientific symposium today, on Thursday, August 16, 2018 during the 10th Annual Bioprocessing Summit, in Boston, Massachusetts.
The presentation, titled, “Manufacturing Strategy for Chemotherapy-Resistant Gamma Delta T Cells for Treatment of Glioblastoma” will be presented at 11:45 a.m. Eastern Daylight Time, on Thursday, August 16, 2018.
|Session Title:||Beyond CAR-T: Manufacturing TILS and T Cells|
|Presentation Title:||Manufacturing Strategy for Chemotherapy-Resistant γδ T Cells for Treatment of|
|Date and Time:||Thursday, August 16, 2018, 11:45 a.m. EDT|
|Speaker:||Lawrence S. Lamb, Ph.D.|
|Abstract:||TMZ-resistant γδ T cells, injected in the post-resection tumor bed|
simultaneously with intravenous TMZ therapy, provide an active response to
GBM when the tumor is in its most vulnerable state. We will discuss
manufacturing operations for γδ T cell manufacturing and MGMT gene
modification for our Phase I clinical trial.
About Bioprocessing Summit 2018
The Bioprocessing Summit convenes more than 1,000 international bioprocess professionals to share practical solutions for today's bioprocess challenges. Now in its tenth year, the event has grown to include 17 distinct conferences with week-long programming on upstream and downstream processing, analytical development and quality, formulation and stability, cell and gene therapy production, and manufacturing. For more information on Bioprocessing Summit 2018, please visit: http://www.bioprocessingsummit.com/.
About Incysus Therapeutics, Inc.
Incysus is focused on delivering a novel off-the-shelf cell therapy for the treatment of cancer. By using genetically modified gamma-delta (γδ) T cells, the Company’s technology addresses the challenges that immunotherapies face targeting cold, low mutation cancers. Incysus’ immuno-oncology programs include activated and gene-modified adoptive cellular therapies that protect cells from chemotherapy and allow novel combinations to disrupt the tumor microenvironment and more selectively target cancer cells. Since the Company’s inception in early 2016, Incysus has filed two Investigational New Drug applications (IND) and has initiated several cancer programs in early pre-clinical stages. The Company’s first program is targeted to leukemia and lymphoma patients and the IND related to this program was approved by the FDA in October 2017. The Company’s second program is targeted to treat patients with newly-diagnosed glioblastoma (GBM). An IND was filed earlier this year. In collaboration with the University of Alabama at Birmingham (UAB), Incysus has advanced its technology and expects to enter the clinic this year. For more information, visit www.incysus.com.
Incysus Therapeutics, Inc.